Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP101 for Prevention of Recurrent C. Difficile Infection
NCT05153499Phase 3Terminated
- Sponsor
- Finch Therapeutics
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 3 trial of CP101 in recurrent Clostridioides difficile infection (rCDI), sponsored by Finch Therapeutics. Started Nov 2021; status: terminated.
02
Drugs
CP101
03
Conditions
recurrent Clostridioides difficile infection (rCDI)
Beyond the preview
Go deeper on NCT05153499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153499.